Skip to main content
Clinical Trials/NL-OMON38312
NL-OMON38312
Completed
Not Applicable

Prediction of short-term outcome in pregnant women with suspected preeclampsia study - PROGNOSIS

Roche Diagnostics GmbH0 sites125 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
preeclampsia
Sponsor
Roche Diagnostics GmbH
Enrollment
125
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Pregnant women \>\=18 years
  • Gestational week 24\+0 days \- 36\+6 days
  • Signed written informed consent
  • Suspicion of clinical diagnosis of PE based on one or more of the following criteria:
  • \- New onset of elevated blood pressure (BP)
  • \- Aggravation of preexisting hypertension
  • \- New onset of protein in urine
  • \- Aggravation of preexisting proteinuria
  • \- One or more other reason(s) for clinical suspicion of PE:
  • PE\-related symptoms: epigastric pain, excessive edema, severe swelling (face, hands, feet), headache, visual disturbances, sudden weight gain (\>1 kg/week)

Exclusion Criteria

  • Proteinuria \>\=2\+ (dipstick) (or in case available \>\=0\.3 g protein/24 hours or \>\=30 mg/dL protein in spot urine or spot urine protein/creatinine ratio \>\=30 mg protein/mmol creatinine) AND elevated BP (\>\=140 mmHg systolic and/or \>\=90 mmHg diastolic, reproducible on two occasions)
  • Proteinuria \>\=2\+ (dipstick) (or in case available \>\=0\.3 g protein/24 hours or \>\=30 mg/dL protein in spot urine or spot urine protein/creatinine ratio \>\=30 mg protein/mmol creatinine) AND current anti hypertensive treatment
  • Confirmed diagnosis of HELLP syndrome
  • Concomitant participation in another clinical study (with exception of existing Biobanks as site pecifically agreed upon with RD)
  • Investigational medicinal product received in the past 3 months (90 days)
  • Employee at the investigational site, or relative or spouse of the investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials